Correlation of EGFR or KRAS Mutation Status with 18F-FDG Uptake on PET-CT Scan in Lung Adenocarcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Apr 20

PMID 28422979

Citations 10

Authors

Kazuya Takamochi

Kaoru Mogushi

Hideya Kawaji

Kota Imashimizu

Mariko Fukui

Shiaki Oh

Masayoshi Itoh

Yoshihide Hayashizaki

Weijey Ko

Masao Akeboshi

Kenji Suzuki

Affiliations

Soon will be listed here.

Abstract

Background: 18F-fluoro-2-deoxy-glucose (18F-FDG) positron emission tomography (PET) is a functional imaging modality based on glucose metabolism. The correlation between EGFR or KRAS mutation status and the standardized uptake value (SUV) of 18F-FDG PET scanning has not been fully elucidated.

Methods: Correlations between EGFR or KRAS mutation status and clinicopathological factors including SUVmax were statistically analyzed in 734 surgically resected lung adenocarcinoma patients. Molecular causal relationships between EGFR or KRAS mutation status and glucose metabolism were then elucidated in 62 lung adenocarcinomas using cap analysis of gene expression (CAGE), a method to determine and quantify the transcription initiation activities of mRNA across the genome.

Results: EGFR and KRAS mutations were detected in 334 (46%) and 83 (11%) of the 734 lung adenocarcinomas, respectively. The remaining 317 (43%) patients had wild-type tumors for both genes. EGFR mutations were more frequent in tumors with lower SUVmax. In contrast, no relationship was noted between KRAS mutation status and SUVmax. CAGE revealed that 4 genes associated with glucose metabolism (GPI, G6PD, PKM2, and GAPDH) and 5 associated with the cell cycle (ANLN, PTTG1, CIT, KPNA2, and CDC25A) were positively correlated with SUVmax, although expression levels were lower in EGFR-mutated than in wild-type tumors. No similar relationships were noted with KRAS mutations.

Conclusions: EGFR-mutated adenocarcinomas are biologically indolent with potentially lower levels of glucose metabolism than wild-type tumors. Several genes associated with glucose metabolism and the cell cycle were specifically down-regulated in EGFR-mutated adenocarcinomas.

Citing Articles

Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

Hu N, Yan G, Wu Y, Wang L, Wang Y, Xiang Y Front Oncol. 2022; 12:879341.

PMID: 36276079 PMC: 9582655. DOI: 10.3389/fonc.2022.879341.

The predictive value of F-FDG PET/CT in an -mutated lung adenocarcinoma population.

Wang J, Wen X, Yang G, Cui Y, Hao M, Qiao X Transl Cancer Res. 2022; 11(7):2338-2347.

PMID: 35966305 PMC: 9372223. DOI: 10.21037/tcr-22-1726.

Prognostic impact of an integrative analysis of [F]FDG PET parameters and infiltrating immune cell scores in lung adenocarcinoma.

Choi J, Sarker A, Choi H, Lee D, Im H EJNMMI Res. 2022; 12(1):38.

PMID: 35759068 PMC: 9237200. DOI: 10.1186/s13550-022-00908-9.

Can F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis.

Du B, Wang S, Cui Y, Liu G, Li X, Li Y BMJ Open. 2021; 11(6):e044313.

PMID: 34103313 PMC: 8190055. DOI: 10.1136/bmjopen-2020-044313.

Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review.

Abdurixiti M, Nijiati M, Shen R, Ya Q, Abuduxiku N, Nijiati M Br J Radiol. 2021; 94(1122):20201272.

PMID: 33882244 PMC: 8173688. DOI: 10.1259/bjr.20201272.

References

van Baardwijk A, Dooms C, van Suylen R, Verbeken E, Hochstenbag M, Dehing-Oberije C . The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007; 43(9):1392-8. DOI: 10.1016/j.ejca.2007.03.027. View

Forrest A, Kawaji H, Rehli M, Baillie J, de Hoon M, Haberle V . A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462-70. PMC: 4529748. DOI: 10.1038/nature13182. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Murata M, Nishiyori-Sueki H, Kojima-Ishiyama M, Carninci P, Hayashizaki Y, Itoh M . Detecting expressed genes using CAGE. Methods Mol Biol. 2014; 1164:67-85. DOI: 10.1007/978-1-4939-0805-9_7. View

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

Huang C, Yen R, Cheng M, Hsu Y, Wei P, Tsai Y . Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2009; 27(1):9-15. DOI: 10.1007/s12032-008-9160-1. View

Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I . 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med. 2005; 46(2):267-73. View

Anders S, Huber W . Differential expression analysis for sequence count data. Genome Biol. 2010; 11(10):R106. PMC: 3218662. DOI: 10.1186/gb-2010-11-10-r106. View

Tsao A, Tang X, Sabloff B, Xiao L, Shigematsu H, Roth J . Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2007; 1(3):231-9. DOI: 10.1016/s1556-0864(15)31573-2. View

10.

Takamochi K, Ohmiya H, Itoh M, Mogushi K, Saito T, Hara K . Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung. BMC Cancer. 2016; 16(1):760. PMC: 5041559. DOI: 10.1186/s12885-016-2792-1. View

11.

Arner E, Daub C, Vitting-Seerup K, Andersson R, Lilje B, Drablos F . Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science. 2015; 347(6225):1010-4. PMC: 4681433. DOI: 10.1126/science.1259418. View

12.

Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M . An atlas of active enhancers across human cell types and tissues. Nature. 2014; 507(7493):455-461. PMC: 5215096. DOI: 10.1038/nature12787. View

13.

Huang D, Sherman B, Lempicki R . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008; 37(1):1-13. PMC: 2615629. DOI: 10.1093/nar/gkn923. View

14.

Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M . FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000; 41(1):85-92. View

15.

Vesselle H, Schmidt R, Pugsley J, Li M, Kohlmyer S, Vallires E . Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000; 6(10):3837-44. View

16.

Thiede C, Bayerdorffer E, Blasczyk R, Wittig B, Neubauer A . Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res. 1996; 24(5):983-4. PMC: 145732. DOI: 10.1093/nar/24.5.983. View

17.

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S . Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. PMC: 545600. DOI: 10.1186/gb-2004-5-10-r80. View

18.

Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriyama S, Yano M . Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Rep. 2011; 5(3):599-602. DOI: 10.3892/mmr.2011.736. View

19.

Stroobants S, Verschakelen J, Vansteenkiste J . Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol. 2002; 45(1):49-59. DOI: 10.1016/s0720-048x(02)00282-6. View

20.

Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y . [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005; 7(4):369-79. PMC: 1501150. DOI: 10.1593/neo.04577. View